Cai, L., Zhang, J., Yao, X., Gu, J., Liu, Q., Zheng, M., . . . Patekar, M. (2020). Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis. Chin Med J (Engl).

Cai, Lin, et al. "Secukinumab Demonstrates High Efficacy and a Favorable Safety Profile Over 52 Weeks in Chinese Patients With Moderate to Severe Plaque Psoriasis." Chin Med J (Engl) 2020.

Cai, Lin, et al. "Secukinumab Demonstrates High Efficacy and a Favorable Safety Profile Over 52 Weeks in Chinese Patients With Moderate to Severe Plaque Psoriasis." Chin Med J (Engl) 2020.